

North Staffordshire and Stoke-on-Trent Area Prescribing Committee

Medicine Review Summary

Rasagiline for the treatment of Parkinson's Disease

Verdict:	
Formulary inclusion:	Rasagiline is to be included in the North Staffordshire Joint Formulary
Formulary category:	Amber 2
Restrictions:	To be initiated by the Specialist
Reason for inclusion:	The committee was satisfied with the safety and cost effectiveness of rasagiline. The committee also noted the clinical practice indicated it was already being use. The Specialists intended rasagiline to be used in specific patients where the mildly stimulant and hallucinogenic effects of selegiline are proving problematic.
Link to formulary:	Stoke-on-Trent CCG website: https://www.stokeccg.nhs.uk/stoke-governance/policies/medicines-optimisation/joint-formulary North Staffordshire CCG website: https://www.northstaffscg.nhs.uk/governance/policies/medicines-optimisation/joint-formulary Secondary care: Trust Intranet → Clinicians → Support services → Pharmacy → North Staffordshire Joint Formulary
Link to medicine review summary:	Stoke-on-Trent CCG website: https://www.stokeccg.nhs.uk/stoke-governance/policies/medicines-optimisation/formulary-review-and-verdict-sheets North Staffordshire CCG website: https://www.northstaffscg.nhs.uk/governance/policies/medicines-optimisation/formulary-review-and-verdict-sheets Secondary care: Trust Intranet → Clinicians → Support services → Pharmacy → Joint Formulary Related Documentation → North Staffordshire & Stoke-on-Trent Area Prescribing Committee Medicine Review Summary Verdict Sheets
Link to full review:	Stoke-on-Trent CCG website: https://www.stokeccg.nhs.uk/stoke-governance/policies/medicines-optimisation/formulary-review-and-verdict-sheets North Staffordshire CCG website: https://www.northstaffscg.nhs.uk/governance/policies/medicines-optimisation/formulary-review-and-verdict-sheets Secondary care: Trust Intranet → Clinicians → Support Services → Pharmacy → Joint Formulary Related Documentation → New Medicine Committee (NMC) Medicines Reviews

Review summary:

Dr Ellis has requested for safinamide to be considered for inclusion in the North Staffordshire Joint Formulary for treatment of Parkinson's disease (PD) where selegiline and rasagiline are inappropriate; however rasagiline is not currently on the formulary.

Rasagiline was previously reviewed in July 2011 and was not approved by the Area Prescribing Committee (APC) for inclusion within the North Staffordshire Joint Formulary as there was insufficient evidence available to suggest that rasagiline was more effective than less expensive selegiline. The economic case for rasagiline needs to be reviewed; rasagiline is now available generically.

Licensed indications:

Rasagiline is indicated in adults for the treatment of idiopathic Parkinson's disease as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Related Guidance:

NICE Clinical Guideline¹: <https://www.nice.org.uk/Guidance/NG71>

Midlands Therapeutics Review and Advisory Committee²: <http://ccg.centreformedicinesoptimisation.co.uk/mtrac/committee-recommendations>

Efficacy and safety:

There is no updated guidance available on rasagiline from NICE, SIGN, SMC, RDT, MTRAC or Cochrane since July 2011. There are no new trials comparing rasagiline with other MAO-B inhibitors.

North Staffordshire and Stoke-on-Trent Area Prescribing Committee

Medicine Review Summary

Costs:**Comparative Costs of MAO-B inhibitors in primary and secondary care (UHNM)**

Medicines Description	Dose	Pack Size	Primary Care (excl. VAT)	UHNM (incl. VAT)
RASAGILINE 1mg TABLETS	1mg OD	28	£1.59	
SELEGILINE 5mg TABLETS	5-10mg OD	100	£16.52	
SELEGILINE 10mg TABLETS	5-10mg OD	100	£32.23	
SELEGILINE 1.25mg ORODISPERSIBLE TABLETS (ZELAPAR)	1.25mg OD	30	£43.16	
SAFINAMIDE 50mg TABLETS (XADAGO)	50-100mg OD	30	£69.00	
SAFINAMIDE 100mg TABLETS (XADAGO)	50-100mg OD	30	£69.00	

References:

¹ National Institute for Health and Clinical Excellence (NICE) NG71. Parkinson's disease in Adults. July 2017. Access online via: <https://www.nice.org.uk/Guidance/NG71>

² Midlands Therapeutics Review and Advisory Committee. Verdict and Summary: Rasagiline (Azilect®) for the treatment of Parkinson's Disease. January 2006. Accessed online via: <http://ccg.centreformedicinesoptimisation.co.uk/mtrac/committee-recommendations>